"Lund-based MedVasc has announced they have successfully completed production and testing activities in accordance with its plan. In parallel, the company closed a new financing round at the end of 2025, raising € 2.2 million (SEK 24 million) from existing shareholders. With the financing secured, MedVasc is well positioned to accelerate the remaining key activities required for FDA clearance of Solutio™ for the U.S. market. Preparations are progressing according to plan, and market approval is expected during autumn 2026."
""The strong participation from current owners demonstrates continued confidence in MedVasc's strategy, execution capability, and long-term value creation. The board and management view this support as a clear validation of the company's direction and its ongoing development efforts," says Cathrin Johansson, CEO of MedVasc Solutio™ is developed to provide painless and precise local anesthesia during thermal treatment of venous insufficiency. The anesthesia catheter is compatible with so-called gold standard treatment fibers (RF/Laser) worldwide."
MedVasc, based in Lund, completed production and testing activities according to plan. The company closed a financing round at the end of 2025, raising €2.2 million (SEK 24 million) from existing shareholders. The financing enables acceleration of remaining activities required for FDA clearance of Solutio™ for the U.S. market. Preparations are progressing according to plan, with market approval expected during autumn 2026. Strong participation from current owners demonstrates continued confidence in MedVasc’s strategy, execution capability, and long-term value creation. Board and management view the investor support as validation of the company's direction and ongoing development efforts. Solutio™ provides painless, precise local anesthesia for thermal venous treatments and is compatible with RF and laser fibers.
Read at resund Startups
Unable to calculate read time
Collection
[
|
...
]